583-08-4

Basic information

• Product Name: NICOTINOYL-GLYCINE
• Synonyms: NICOTINYLGLYCINE;NICOTINOYL-GLYCINE;NICOTINOYL-GLY-OH;NICOTINURIC ACID;NICOTINICAMIDO ACETIC ACID;N-(pyridin-3-ylcarbonyl)glycine;N-NICOTINOYLGLYCINE;N-NicotinuricAcid~99%
• CAS NO: 583-08-4
• Molecular Formula: C₈H₈N₂O₃
• Molecular Weight: 180.16
• EINECS: 209-497-0
• Product Categories: Amino Acids;Amino Acids 13C, 2H, 15N;Amino Acids & Derivatives;Aromatics;Heterocycles
• Mol File: 583-08-4.mol
• Article Data: 7

Chemical Properties

• Melting Point: 256-2580C (dec.)
• Boiling Point: 512.5 °C at 760 mmHg
• Flash Point: 263.7 °C
• Appearance: white solid
• Density: 1.343 g/cm³
• Vapor Pressure: 2.51E-11mmHg at 25°C
• Refractive Index: 1.572
• Storage Temp.: Store at 0-5°C
• Solubility: Aqueous Base (Slightly), DMSO (Slightly), Methanol (Slightly, Heated, Sonicated)
• PKA: 3.10±0.10(Predicted)
• Water Solubility: Soluble in dimethyl sulfoxide, methanol, water, and 1M NH4OH (50 mg/mL).
• CAS DataBase Reference: NICOTINOYL-GLYCINE(CAS DataBase Reference)
• NIST Chemistry Reference: NICOTINOYL-GLYCINE(583-08-4)
• EPA Substance Registry System: NICOTINOYL-GLYCINE(583-08-4)

Safety Data

• Hazard Codes: Xi
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 583-08-4(Hazardous Substances Data)

Usage

Chemical Properties

White Solid

Uses

Different sources of media describe the Uses of 583-08-4 differently. You can refer to the following data:
1. N-Nicotinoylglycine can be used to antiproliferative and as a Niacin analog for therapeutic use.
2. A Niacin analog for therapeutic use. Antiproliferative.

Definition

ChEBI: An N-acylglycine having nicotinoyl as the acyl substituent.

InChI:InChI=1/C8H8N2O3/c11-7(12)5-10-8(13)6-2-1-3-9-4-6/h1-4H,5H2,(H,10,13)(H,11,12)

Upstream product

• 4013-72-3 nicotinoyl azide 
• 56-40-6 glycine 
• 54466-74-9 N³-((ethoxycarbonyl)-methyl)nicotinamide 
• 20260-53-1 pyridine-3-carbonyl chloride hydrochloride 
• 59-67-6 nicotinic acid 
• 1037820-84-0 nicotinyl-glycine-tert-butyl ester 
• 78348-28-4 nicotinic acid succinimidyl ester 
• 98-92-0 nicotinamide 
• 79-11-8 chloroacetic acid 
• 553-53-7 Nicotinic acid hydrazide 
• 10400-19-8 3-pyridinecarbonyl chloride 

Downstream Products

• 124-38-9 carbon dioxide 
• 98-92-0 nicotinamide 
• 144-62-7 oxalic acid 
• 59-67-6 nicotinic acid 
• 56-40-6 glycine 
• 347184-14-9 N-{[3-(9-Chloro-3-methyl-4oxo-5H-isoxazolo[4,3-c]quinolin-5-yl)-cyclohexylcarbamoyl]-methyl}-nicotinamide 
• 105959-39-5 4-((4-azidophenyl)methylene)-2-(3-pyridyl)-1,3-oxazolin-5-one 
• 606142-93-2 4-(4-azido-β-methyl-cinnamylidene)-2-(3-pyridyl)-2-oxazolin-5-one 
• 1421066-84-3 C₃₂H₃₈N₄O₃ 

Relevant articles and documents

New compounds: convenient preparation of nicotinoyl glycine derivatives.

-

niacine or niacinamide substituted ascorbic acid derivatives and process for their preparation

PURPOSE: An ascorbic acid derivative in which niacinamide or niacine is introduced and a method for preparing the same are provided to enhance organic solvent solubility and efficiency. CONSTITUTION: A 3-O-substituted ascorbic acid derivative is denoted by chemical formula 1. A method for preparing the 3-O-substituted ascorbic acid derivative of chemical formula 1 comprises: a step of reacting 5,6-alkylidene ascorbic acid derivative with an acid derivative of chemical formula 2 in an organic solvent; and a step of deprotecting under the presence of carbodiimide of chemical formula 4. The organic solvent is amides, sulfoxides, alcohols, ethers, ketones, halogenated hydrocarbons, or fatty acid organic acid.

Synthesis and biological evaluation of novel hydrogen sulfide releasing nicotinic acid derivatives

Twelve novel hybrids of slowly releasing hydrogen sulfide donor ADT-OH combined with nicotinic acid were synthesized. All of their structures had been confirmed by1H NMR,13C NMR and MS spectra. The target compounds were evaluated for their neuroprotective effects on hippocampal neuron HT22 cells against glutamate-induced injury at the concentrations of 1–100?μM with MTT assay, and their toxicity on HT22 cells untreated by glutamine at the concentration of 100?μM. The active compound was further investigated for its effect on ischemic infarct volume by intraperitoneal injection at 3?h after ischemia in mice models of permanent middle cerebral artery occlusion (pMCAO). The results showed that all the compounds significantly protected HT22 cells from glutamate-induced damage at most of the experimental concentrations, and had no or little neurotoxicity on normal HT22 cells at the high concentration. More importantly, compound A6 significantly reduced infarct volume in the pMCAO model. These results suggested that compound A6 may be promising for further evaluation for the intervention of cerebral ischemic injury.